Publicly funded dose-reduction trials of expensive approved drugs
Many approved cancer drugs probably work just as well at half the dose, which would halve their side effects and cost. Companies will not test this, so payers and public funders should.
Payers and public agencies fund randomised non-inferiority trials of reduced doses or less frequent schedules of high-cost approved agents, prioritised by spend and by pharmacological plausibility (saturated target, flat exposure-response, long half-life). Precedents include reduced-dose abiraterone with food and reduced-dose or extended-interval checkpoint inhibitors. Results are used directly in reimbursement.
- Wrong doses · Most drug doses were chosen as the highest a person can tolerate, which is often more than they need.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Wrong doses, Prices and value, Nivolumab, Pembrolizumab.
- IdeaPublicly funded trials of lower and less frequent doses of expensive cancer drugs
Shares Wrong doses, Prices and value, Nivolumab, Pembrolizumab.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Prices and value, Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Prices and value, Nivolumab, Pembrolizumab.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Wrong doses, Prices and value, Nivolumab, Pembrolizumab.
- IdeaModel-informed individual dosing with drug-level monitoring for every oral cancer drug
Shares Imatinib, Wrong doses, Small-molecule kinase inhibitors.
- IdeaMeasure blood levels of oral targeted drugs and adjust doses to a target range
Shares Imatinib, Wrong doses, Small-molecule kinase inhibitors.